Objective  To analyze the effects of urinastatin combined with continuous renal replacement therapy on inflammatory factors, oxidative stress level and immune indexes in patients with urogenous sepsis.Methods  From April 2018 to April 2020, 60 patients with urogenous sepsis in our hospital were selected as the subjects, and they were divided into two groups according to the order of admission, among them, 29 patients in the control  group were treated with routine treatment+continuous renal replacement treatment, and 31 patients in the study group were treated with routine treatment+continuous renal replacement treatment+urinastatin. The changes of serum creatinine，urea, inflammatory factors, oxidative stress and immune indexes were compared between the two groups.Results  After treatment, CD3⁺, CD4⁺, CD4⁺/CD8⁺ of the two groups were higher than those before treatment (all P<0.05), and CD8⁺ was lower than that before treatment (P<0.05), meanwhile, after treatment, CD3⁺, CD4⁺, CD4⁺/CD8⁺ in the study group were higher than those in the control group (all P<0.001), and CD8⁺ was lower than that in the control group (P<0.001). The results of serum creatinine and blood urea in the two groups after treatment were lower than those before treatment (all P<0.05), and the results of serum creatinine and blood urea in the study group after treatment were lower than those in the control group (all P<0.05). After treatment, the levels of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10) and interleukin-1β (IL-1β) were lower than those before treatment (all P<0.05), and after treatment, the levels of TNF-α, IL-10 and IL-1β in the study group were lower than those in the control group (all P<0.05). After treatment, the malondialdehyde (MDA) was lower than that before treatment, and superoxide dismutase (SOD) and catalase (CAT) were lower than those before treatment (all P<0.05), meanwhile, after treatment, MDA in the study group was lower than that in the control group (P<0.05), and SOD and CAT were higher than those in the control group (all P<0.05). Conclusions  Urinastatin combined with continuous renal replacement therapy for urogenous sepsis can reduce the levels of inflammation and oxidative stress, and improve the renal function and immune function.